A novel mutation in the tyrosine kinase domain of ERBB2 in hepatocellular carcinoma

@article{BekaiiSaab2006ANM,
  title={A novel mutation in the tyrosine kinase domain of ERBB2 in hepatocellular carcinoma},
  author={Tanios S. Bekaii-Saab and Nita Williams and Christoph Plass and Miguel Villalona Calero and Charis Eng},
  journal={BMC Cancer},
  year={2006},
  volume={6},
  pages={278 - 278}
}
Several studies showed that gain-of-function somatic mutations affecting the catalytic domain of EGFR in non-small cell lung carcinomas were associated with response to gefitinib and erlotinib, both EGFR-tyrosine kinase inhibitors. In addition, 4% of non-small cell lung carcinomas were shown to have ERBB2 mutations in the kinase domain. In our study, we sought to determine if similar respective gain-of-function EGFR and ERBB2 mutations were present in hepatoma and/or biliary cancers. We… CONTINUE READING
23 Citations
22 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 23 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 22 references

Similar Papers

Loading similar papers…